Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas

Endocrine Journal

Volumn 56, Issue 2, 2009, Pages 295-304

  Nakashima, Michi ^a   Takano, Koji ^b   Matsuno, Akira ^a  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Gh secreting adenoma; Gsp mutation; Ki 67 staining index; Octreotide; Somatostatin receptor type 2a

Indexed keywords

KI 67 ANTIGEN; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT;

ADULT; AGED; CELL MEMBRANE; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN; REGRESSION ANALYSIS;

EID: 66849135261     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K08E-305     Document Type: Article

References (21)

1. Kontogeorgos G (2006) Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83: 179-188.
2. Takei M, Suzuki M, Kajiya H, Ishii Y, Tahara S, Miyakoshi T, Egashira N, Takekoshi S, Sanno N, Teramoto A, Osamura RY (2007) Immunohistochemi- cal detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide. Endocr Pathol 18: 208-216.
3. Fougner SL, Borota OC, Berg JP, Hald JK, Ramm- Pettersen J, Bollerslev J (2008) The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf) 68: 458-465.
4. Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ (2008) Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin EndocrinolMetab 93: 1412-1417.
5. Adams EF, Lei T, Buchfelder M, Petersen B, Fahlbusch R (1995) Biochemical characteristics of human pituitary somatotropinomas with and without gsp mutations: in vitro cell culture studies. J Clin Endocrinol Metab 80: 2077-2081.
6. Yang I, Park S, Ryu M, Woo J, Kim S, Kim J, Kim Y, Choi Y (1996) Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acrome- galic patients. Eur J Endocrinol 134: 720-726.
7. Faglia G, Arosio M, Spada A (1996) Gs protein mutations and pituitary tumors: functional correlates and possible therapeutic implications. Metabolism 45: 117119.
8. Spada A, Faglia G (1996) G-protein dysfunction in pituitary tumors. In: Melmed S (ed) Oncogenesis and Molecular Biology of Pituitary Tumors. Karger, Basel, Switzerland, 108-121.
9. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A, Jaquet P (1998) Prognostic and therapeutic consequences of Gsa mutations in somatotroph adenomas. J Clin Endocrinol Metab 83: 1604-1610.
10. Yasufuku-Takano J, Takano K, Morita K, Takakura K, Teramoto A, Fujita T (2006) Does the prevalence of gsp mutations in GH-secreting adenomas differ geographically or racially? Prevalence of gsp mutation in Japanese patients revisited. Clin Endocrinol (Oxf) 64: 91-96.
11. Lloyd RV, Kovacs K, Young WF Jr., Farrell WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E (2004) Pituitary tumors; Introduction. In: Dellis RA, Lloyd RV, Heitz PU, Eng C (eds) WHO Classification of Tumors. Pathology and Genetics. Tumors of Endocrine Organs. IARC Press, Lyon, 10-13.
12. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr. (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38: 99-106; discussion 106-107.
13. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, Schlumberger M, Rougier P (2001) Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 37: 1014-1019.
14. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M, Faglia G (1990) Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71: 1421-1426.
15. Adams EF, Brockmeier S, Friedmann E, Roth M, Buchfelder M, Fahlbusch R (1993) Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. Neurosurgery 33: 198-200.
16. Patel YC, Greenwood M, Kent G, Panetta R, Skribant CB (1993) Multiple gene transcripts of the somato- statin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun 192: 288-294.
17. Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jaquet F, Enjalbert A (1999) Impact of gsp oncogene on the expression of genes coding for Gsa, Pit-1, Gi2a, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 84: 2759-2765.
18. Corbetta S, Ballare E, Mantovani G, Lania A, Losa M, Di Blasio AM, Spada A (2001) Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Invest 31: 208-214.
19. Bertherat J, Chanson P, Montminy M (1995) The cyclic adenosine 3',5'-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocinol 9: 777-783.
20. Yang X, Lee FYG, Wand GS (1997) Increased expression of Gsa enhances activation of the adenylyl cyclase signal transduction cascade. Mol Endocrinol 11: 1053-1061.
21. Hamacher C, Brocker M, Adams EF, Lei T, Fahlbusch R, Buchfelder M, Derwahl M (1998) Overexpression of stimulatory G protein a-subunit is a hallmark of most human somatotrophic pituitary tumours and is associated with resistance to GH-releasing hormone. Pituitary 1: 13-23.